Table 1.

Clinical characteristics, prior cytotoxic exposures, and therapy-related leukemia characteristics of 88 breast cancer survivors

	Number (%)
Age at diagnosis of breast cancer
≤35	9 (10)
36–45	14 (16)
46–55	29 (33)
≥56	34 (39)
Unknown	2 (2)
Race/Ethnicity
Caucasian (non-AJ)	65 (74)
Caucasian (AJ)	3 (3)
African American	5 (6)
Other/Unknown	15 (17)
Additional cancer diagnoses (n=19)*
Second primary breast cancer	7 (8)
Ovarian cancer	3 (3)
Other	12 (14)
Family history of cancer in a first or second degree relative (n=70)
Breast cancer	33 (47)
Breast, ovarian, or pancreatic cancer	40 (57)
Prior therapy
Chemotherapy + Radiation	49 (56)#
Chemotherapy only	18 (20)#
Radiation only	19 (22)
Unknown	2 (2)
Chemotherapy class exposures
Topoisomerase II inhibitor	40 (45)
Alkylating agent	58 (66)
Unknown	8 (9)
Type of therapy-related leukemia
t-MN	81 (92)
t-ALL	7 (8)
Latency; median in months (IQR) **	58 (28–105)
Cytogenetics***
Normal karyotype	7 (8)
Abnormal karyotype	77(88)
Abnormalities of chromosome 5 and/or 7	43 (49)
Recurring balanced translocations	29 (33)
Other clonal abnormality	7 (8)
Unknown	4 (5)
Overall survival; median in months (IQR)
From breast cancer diagnosis****	102 (60–173)
From therapy-related leukemia diagnosis	13 (5–22)

^*Includes three women with multiple primary tumors; other cancers include: uterine (n=2), melanoma (n=2), lung (n=2), non-Hodgkin lymphoma (n=2), osteosarcoma (n=1), bladder (n=1), cervical (n=1), multiple myeloma (n=1)

^#Specific agents were unknown for n=4 in the chemotherapy + radiation group and n=2 in the chemotherapy only group

^**Latency was unknown for 3 patients

^***2 patients had abnormalities of both chromosomes 5 and/or 7 and a recurring balanced translocation (t(15;17) and t(9;22))

^****Overall survival was unknown for 3 patients

Abbreviations: AJ=Ashkenazi Jewish; t-MN=therapy-related myeloid neoplasm; t-ALL=therapy-related acute lymphoblastic leukemia; IQR=interquartile range